About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, RP-323, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

December 28

Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS View Release

November 23

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA) View Release

October 7

Rich Pharmaceuticals Retains Theradex Systems To Finalize Investigational New Drug Application And Initiate Next Phases Of Clinical Trials View Release

» Read Latest News